EC Number | Application | Comment | Organism |
---|---|---|---|
3.4.15.1 | medicine | ACE inhibition is a therapeutic target in treating peripheral occlusive arterial disease | Rattus norvegicus |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
3.4.15.1 | quinapril | 18 mg/kg quinapril per day feeding for 3 days significantly reduces blood plasma ACE activity by 80%, quinapril administration for 16 days greatly decreases blood plasma ACE activity by 88% with 18 mg/kg per day, ACE activities in the heart, lung, and skeletal muscles of the 16-day ACE-inhibition with 18 mg/kg per day are 9%, 16%, and 22% of the controls, respectively | Rattus norvegicus |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.4.15.1 | angiotensin I + H2O | Rattus norvegicus | - |
angiotensin II + L-His-L-Leu | - |
? | |
3.4.15.1 | bradykinin + H2O | Rattus norvegicus | - |
? | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.4.15.1 | Rattus norvegicus | - |
- |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
3.4.15.1 | blood plasma | - |
Rattus norvegicus | - |
3.4.15.1 | heart | - |
Rattus norvegicus | - |
3.4.15.1 | lung | - |
Rattus norvegicus | - |
3.4.15.1 | skeletal muscle | - |
Rattus norvegicus | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.4.15.1 | angiotensin I + H2O | - |
Rattus norvegicus | angiotensin II + L-His-L-Leu | - |
? | |
3.4.15.1 | bradykinin + H2O | - |
Rattus norvegicus | ? | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
3.4.15.1 | ACE | - |
Rattus norvegicus |
3.4.15.1 | angiotensin converting enzyme | - |
Rattus norvegicus |
3.4.15.1 | DCP | - |
Rattus norvegicus |